PASI, BSA Involvement, and QoL Scales Best to Determine Psoriasis Severity

No statistically significant correlation was found between physical psoriasis assessment scales with frequently used quality of life (QoL) scales in patients with psoriasis, suggesting both disease severity and QoL should be assessed in determining the severity of psoriasis, according to study findings published in the Journal of Cosmetic Dermatology.

This cross-sectional study was an analysis of 51 patients with chronic plaque-type psoriasis who required systemic therapy and were referred to a clinic from 2014 to 2016. The investigators calculated the patients’ Psoriasis Area and Severity Index (PASI), body surface area (BSA) involvement, Dermatology Life Quality Index (DLQI), and Psoriasis Disability Index (PDI) values.

Overall, the mean age of the patient population was 44.76±11.14 years, and the mean duration of disease was 20.74±7.94 years. On average, the age at disease onset was 24.01±10.75 years. The mean PASI value, BSA involvement, DLQI, and PDI values were 17.27±7.49, 33.90±13.87, 15.09±7.48, and 23.58±10.20, respectively.

There were no significant differences between the scales among patients with vs without involvement in the hand, face, nail, foot, and genital area (P range=.083-.990). The PASI correlated with BSA involvement in the Spearman test (P =.000) but did not correlate with DLQI (P =.227) and PDI (P =.208). There was no correlation between BSA involvement and DLQI (P =.312) and PDI (P =.228), but the investigators did find a correlation between DLQI and PDI (P =.000).

Limitations of this study include its cross-sectional nature as well as the inclusion of only a small number of patients.

The researchers concluded that these findings show “the significance of using PASI, BSA, and quality of life scales together in determining disease severity.”


Gundogdu M, Kundakci N. Evaluation of the correlation between scales determining disease severity in patients with moderate-severe chronic plaque-type psoriasis. Published online November 3, 2020. J Cosmet Dermatol. doi:10.1111/jocd.13827